

April 4, 2022 04:01 AM GMT

## US Equity Strategy | North America

# Weekly Warm-up: Boring Is Beautiful with Bear Market Rally Over; Stay Defensively Biased

After one of the roughest quarters in history for stocks and bonds collectively, the markets better reflects the "Fire" part of our narrative; but now it's about the "Ice," and that's decidedly worse for stocks relative to bonds. We are doubling down on defensives, with the bear market rally now over.

**1Q was rough even with the strong finish.** The first quarter was one of the worst on record for the collective performance of stocks and bonds, with the latter worse than the former. This makes sense given investor concern focused more on the "Fire" (inflation and the Fed) than the "Ice" (growth slowdown). However, that leaves us more constructive on bonds than stocks over the near term as growth concerns take center stage – hence our doubling down on a defensive bias.

**The bear market rally is over.** While 1Q was rough for most stocks, the second half of March was exceptionally strong. The rally was predictable from a technical perspective, but it was always a bear market rally in our view, and now we think it's over. Our analysis of Friday's ISM manufacturing survey shows the orders component is now below inventories for the first time since the expansion began. This book to bill proxy for the broader manufacturing sector suggests meaningful downside to the headline ISM over the next few months, which does not bode well for the S&P500.

**Boring is beautiful.** Defensive sectors and stocks have outperformed both growth and value since our 2022 Outlook was published. The exceptions have been Energy and Materials, which have been the biggest beneficiaries of geopolitical turmoil. Despite the windfall for these sectors, defensives have even outperformed cyclicals at the broader level. We think this is further confirmation of our view that defensives remain the place to be. Boring is beautiful and we are doubling down on that theme today with growth and the rally fading into 2Q.

**Market is paying up for dividend yield, not growth – i.e., bond proxies.** Our latest quantitative analysis shows the market has been paying more for dividend yield rather than dividend growth since late last year. We think this is also supportive of our view that growth is becoming the primary concern for equity investors rather than higher rates. Just like the other analysis of market internals we do, this quantitative approach suggests the indices are vulnerable to growth slowing, particularly after the strong rally of the past few weeks.

MORGAN STANLEY &amp; CO. LLC

Michael J Wilson

EQUITY STRATEGIST

M.Wilson@morganstanley.com

+1 212 761-2532

Andrew B Pauker

EQUITY STRATEGIST

Andrew.Pauker@morganstanley.com

+1 212 761-1330

Michelle M. Weaver, CFA

EQUITY STRATEGIST

Michelle.M.Weaver@morganstanley.com

+1 212 296-5254

Diane Ding, Ph.D.

QUANTITATIVE STRATEGIST

Qian.Ding@morganstanley.com

+1 212 761-6758

Nicholas Lentini, CFA

RESEARCH ASSOCIATE

Nick.Lentini@morganstanley.com

+1 212 761-5863

Morgan Stanley does and seeks to do business with companies covered in Morgan Stanley Research. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of Morgan Stanley Research. Investors should consider Morgan Stanley Research as only a single factor in making their investment decision.

For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report.

# What to Focus on This Week

## 1Q Was Rough Even with the Strong Finish

Given how bad first quarter returns were for both stocks *and* bonds, most investors (both asset owners and manager) were probably happy to see it end. Furthermore, the rally in the second half of March made it considerably better for stocks than it was looking just a few weeks ago. In the end, **bond returns ranked much worse than stocks from a historical perspective, with Treasuries posting their worst quarter in 50 years (Exhibit 1).**

**Exhibit 1:** One of the worst quarters since 1973 for stocks and bonds, particularly the latter

	Quarter End	ACWI	Quarter End	SPX	Quarter End	AGG	Quarter End	UST	Quarter End	60/40
1	Dec-08	-22.8%	Sep-74	-26.1%	Mar-80	-8.7%	Mar-22	-5.6%	Dec-08	-11.7%
2	Mar-20	-21.7%	Dec-87	-23.2%	Sep-80	-6.6%	Mar-80	-5.5%	Dec-87	-11.6%
3	Sep-02	-18.6%	Dec-08	-22.6%	Mar-22	-5.9%	Sep-80	-4.6%	Mar-20	-10.7%
4	Sep-90	-18.6%	Mar-20	-20.0%	Sep-81	-4.1%	Mar-21	-4.3%	Sep-02	-8.7%
5	Sep-11	-17.9%	Jun-70	-18.9%	Mar-21	-3.4%	Dec-16	-3.8%	Sep-81	-8.5%
6	Sep-08	-17.1%	Sep-02	-17.6%	Dec-79	-3.1%	Jun-04	-3.2%	Sep-90	-8.4%
7	Sep-01	-15.0%	Sep-01	-15.0%	Dec-16	-3.0%	Mar-94	-3.0%	Dec-18	-7.7%
8	Mar-90	-14.7%	Sep-90	-14.5%	Mar-94	-2.9%	Jun-09	-3.0%	Sep-01	-7.1%
9	Dec-18	-13.1%	Sep-11	-14.3%	Sep-87	-2.7%	Sep-87	-2.9%	Sep-11	-7.1%
10	Mar-01	-12.8%	Dec-18	-14.0%	Jun-04	-2.4%	Dec-10	-2.6%	Mar-09	-7.0%
11	Jun-10	-12.7%	Jun-02	-13.7%	Jun-13	-2.3%	Mar-96	-2.3%	Jun-02	-6.8%
12	Sep-98	-12.7%	Mar-01	-12.1%	Jun-84	-2.1%	Sep-81	-2.2%	Mar-80	-6.7%
13	Mar-09	-11.3%	Sep-75	-11.9%	Jun-87	-1.8%	Jun-08	-2.1%	Mar-01	-6.1%
14	Sep-15	-9.9%	Jun-10	-11.9%	Mar-96	-1.8%	Jun-13	-1.9%	Jun-10	-5.7%
15	Mar-08	-9.7%	Mar-09	-11.7%	Jun-15	-1.7%	Mar-92	-1.8%	Sep-08	-5.5%
16	Jun-02	-9.5%	Sep-81	-11.5%	Mar-18	-1.5%	Jun-87	-1.8%	Mar-77	-5.4%
17	Mar-92	-7.9%	Sep-98	-10.3%	Dec-78	-1.4%	Mar-99	-1.6%	Mar-22	-5.3%
18	Dec-00	-6.8%	Dec-73	-10.0%	Dec-10	-1.3%	Jun-15	-1.6%	Mar-08	-5.1%
19	Jun-12	-6.4%	Mar-08	-9.9%	Mar-92	-1.3%	Mar-90	-1.4%	Sep-98	-4.5%
20	Mar-22	-5.7%	Sep-08	-8.9%	Sep-79	-1.3%	Mar-09	-1.3%	Dec-78	-4.3%

Source: Morgan Stanley Research Cross Asset Team

*More Fire than Ice...*

**The tough 1Q was very much in line with our view coming into 2022 – i.e. we didn't see many fat pitches given the Fed's (and other central banks') resolve to fight the surge in inflation in the face of slowing growth (Tightening Fed and Slowing Growth = Defense).** Whether it was for technical or fundamental reasons, bond and stock markets ignored this risk into year end 2021. Apparently, they required an additional prompt, which the Fed supplied with the minutes of its December meeting on January 5th. From that moment, both stocks and bonds made a sharp U-turn and never really looked back for the entire first month of the year.

**In short, headline indices in stocks and bonds finally adjusted to the Fire part of our narrative, a risk that started to price under the surface in early November when Powell was renominated. With inflation on everyone's mind in 1Q more than any other risk, it makes sense that bonds would be worse than equities.** It also makes sense that stocks most vulnerable to higher rates did even worse than the more diversified S&P 500 index – i.e. the Nasdaq performance was considerably worse than both the S&P 500 and Russell 2000, a very rare occurrence over the past few years. And, this is after a major rally in the past two weeks that was led by the Nasdaq. Our takeaway is that markets were preoccupied with the Fed's sharp pivot more than anything else and it played out in asset prices, appropriately.

*... but now comes the slowdown*

**Of course, the other major driver of markets in Q1 was the war in Ukraine.** While tensions had been building since late last year, it's fair to say markets had ignored this risk as much as the Fed's pivot. The only difference is that the Fed's pivot was well telegraphed while Russia's invasion was far from a sure thing and more of an unknown known to most, including us. Obviously, such an event did materially factor into the risks for 1Q by accentuating the Fire *and* Ice – i.e., it made inflation worse while dampening growth prospects simultaneously. It has also rattled confidence for both businesses and consumers, especially in Europe. **This was not in our calculus when we made our forecasts for 2022. As such, we find ourselves incrementally more negative on growth trends than we were at the end of last year.**

**Last fall we pushed out the timing of the Ice part of our narrative to 1H22** when we realized the economy still had plenty of strength left for companies to deliver on earnings growth. **But, now investors face multiple headwinds to growth that will be harder to ignore** – payback in demand from last year's fiscal stimulus, demand destruction from high prices, food and energy price spikes from the war that serve as a tax, and inventory builds that have now caught up to demand. While the first three headwinds are somewhat appreciated, we think the last one is not. Specifically, we have been highlighting the risk for supply to overwhelm demand in many goods this year while most have viewed the recent build in inventory as mainly a positive that will help tame inflation. While we agree with the premise of that rosy conclusion, we would also warn investors to be careful what you wish for. Inflation has been an elixir for profits for most of this recovery. Until now, companies have had little problem passing along higher costs, hence why we have inflation. However, as supply catches up to demand, pricing power will likely dissipate and discounting could return in many areas of consumer goods that typically are price takers. We're also liable to see cancellation of orders that were doubled up due to the shortages, another theme we have been discussing for months. Semiconductor stocks and other areas of the market that have very fragmented supply chains look to be the most vulnerable in our view.


*The bear market rally is over*

On that score, **Friday's ISM release showed a sharp deterioration in the orders component. Relative to inventories, it looks even worse, with the inventory component of the index now below orders for the first time since the recovery began.** Think of this as a book to bill for the broader manufacturing economy. Based on our Ice and over-ordering thesis, we have been expecting this and now it is here. As we have shown in prior notes, **this differential between the orders and inventories components leads the headline index (Exhibit 2). Importantly for investors, it suggests the S&P 500 has another rough month(s) ahead (Exhibit 3).** Bottom line, the rally in stocks over the past few weeks has been remarkable, but in our view it has all the characteristics of a bear market rally, and we view month/quarter end as the perfect spot for it to come to an end.

Exhibit 2: Orders lead headline...



Exhibit 3: ... Signaling lower S&amp;P 500




*Boring is beautiful*

Based on our Fire and Ice narrative and all of the building evidence to support it, we have been defensively positioned in our strategy recommendations since we published our year ahead outlook back in mid November. While not a straight line, this positioning has worked well and has dominated a growth or cyclicals bias (Exhibit 4 and Exhibit 5). Our big miss was being equal weight Energy although in our Fresh Money Buy list we have effectively been overweight with our 10% position in Exxon as a "defensively" oriented energy stock. Bottom line, defensive positioning has been the right move.

Exhibit 4: Defensives and Energy Dominating



Exhibit 5: While Beating Growth &amp; Value




This defensive domination may surprise readers given the large weighting of Energy within cyclicals and the fact that rates have moved up so much in the past several months. Typically, defensives act poorly in a rising rate environment as they serve as a bond proxy in many ways. However, bond proxies are doing well, especially over the past week when Real Estate and Utilities were the best-performing sectors. It's also worth noting that on the back of Friday's strong labor market report, 30-year bonds rallied 2 points from the intra-day lows. Some of this may be due to the ISM report discussed above but our sense is that the markets are starting to price in our Ice scenario right on cue. As we have written in our recent research, we think 30-year Treasuries offer an excellent hedge against the growth scare we expect now that the Fed is fully priced. Last week's price action seems to support such a view and we're sticking to it with our reiteration of defensive stocks as the place to be. We remain overweight Utilities, REITs and Healthcare. Conversely, we are underweight Consumer Discretionary and

cyclical Tech while keeping equal weights in everything else and focusing on stock picking. Suffice it to say, we are also recommending Defensives over both cyclicals and growth. See more on what's working from a quantitative perspective in the section below.


**With our recent downgrade of Banks, we think the pair of Utilities over Banks looks particularly attractive.** With Banks positively correlated to back end rates, this is another example of the internals of the market saying we close to a top ([Exhibit 6](#) and [Exhibit 7](#)). Obviously, the inversion of the yield curve is also supportive of this relative value trade as it signals late cycle, a time when Utilities dominate early cycle groups like Banks. The pair is also highly correlated to the ISM manufacturing index, which is headed lower in our view ([Exhibit 8](#)).

**Exhibit 6: Why are Banks lagging rates?**



Source: Bloomberg, Morgan Stanley Research

**Exhibit 7: Why is Banks/Utes falling?**



Source: Bloomberg, Morgan Stanley Research

**Exhibit 8: Fins/Utes lead the ISM headline index, which appears to be headed materially lower**




Source: Bloomberg, Morgan Stanley Research

## Quant's Weekly Chart and Factor Update


Investors are paying for high dividend yield rather than high dividend growth. We look at the relative performance of high dividend yield stocks versus high dividend growth stocks in the market, and high dividend yielders have been outperforming high dividend growers since late last year ([Exhibit 9](#)). From an individual factor perspective, high dividend yield stocks outperform low dividend yield stocks since December although the last 2 months have been more bumpy ([Exhibit 11](#)). During the same period, high dividend growth has been underperforming ([Exhibit 12](#)).

**Exhibit 9: High div. yielders outperform high div. growers**




Source: Clarifi, Morgan Stanley Research

**Exhibit 10: ...Shorter term view**




Source: Clarifi, Morgan Stanley Research

**Exhibit 11: High div. yielders outperform low div. yielders since last year end**



Source: Clarifi, Morgan Stanley Research

**Exhibit 12: High div. growers underperform low div. growers**



Source: Clarifi, Morgan Stanley Research

## Factor Update

We select a few key factors to monitor in [Exhibit 13](#) and [Exhibit 14](#) to help study market drivers from a factor standpoint. These Exhibits focus on factors within the US Top 1000 by market cap universe. Some key takeaways on performance in the last month:

- Quality has outperformed Junk (+1.3% relative return); Quality has been one of the best performing factors (out of those listed below) relative to the broad Top 1000 (+0.9% relative outperformance).
- Value has outperformed Growth (+1.5%) and the overall market (+0.5% relative return versus the overall Top 1000 universe).
- Cyclical are up +0.5% in absolute terms, underperforming Defensives (-1.9%); but that performance spread widens when we exclude Energy from Cyclical, which has seen relatively strong performance amid the recent squeeze in crude prices; Cyclical-Ex Energy have underperformed Defensives by -2.7%.
- High Momentum stocks have outperformed low momentum stocks (+0.1% relative return) and the overall market (+0.5% relative return).
- Small Caps have underperformed Large Caps by -1.7%.

**Exhibit 13: Top 1000 Factor Returns**

Top 1000 Factor Return as of Mar 31, 2022				
Factor	1 Week	1 Month	YTD	12 Months
Quality / Junk	0.6%	1.3%	3.1%	13.4%
Quality	0.5%	2.6%	-3.7%	11.5%
Junk	0.0%	1.4%	-6.7%	-1.9%
Value / Growth	0.6%	1.5%	14.8%	18.1%
Value	0.4%	2.3%	1.5%	11.5%
Growth	-0.2%	0.7%	-13.4%	-6.5%
Cyclical / Defensive	-1.9%	-1.9%	-0.6%	-3.5%
Cyclical	-0.8%	0.5%	-5.1%	3.8%
Defensive	1.1%	2.4%	-4.5%	7.2%
Cyclical xEnergy / Defensive	-2.0%	-2.7%	-4.1%	-8.0%
Cyclical xEnergy	-0.9%	-0.4%	-8.6%	-0.8%
12M Momentum	-1.0%	0.1%	-2.1%	3.4%
High Momentum	-0.5%	2.3%	-6.7%	2.0%
Low Momentum	0.5%	2.1%	-4.7%	-1.4%
Size (Small / Large)	-0.2%	-1.7%	-1.6%	-14.7%
Small Cap	0.2%	0.8%	-6.5%	-3.9%
Large Cap	0.4%	2.6%	-4.9%	10.8%

Source: Clarifi, Morgan Stanley Research


**Exhibit 14: Excess Return Versus Broader Top 1000 Universe**

Top 1000 Excess Factor Return versus Broader Top 1000 Return as of Mar 31, 2022				
Factor	1 Week	1 Month	YTD	12 Months
Quality / Junk				
Quality	0.4%	0.9%	2.0%	7.8%
Junk	-0.2%	-0.3%	-1.1%	-5.6%
Value / Growth				
Value	0.2%	0.5%	7.2%	7.8%
Growth	-0.4%	-1.0%	-7.7%	-10.3%
Cyclical / Defensive				
Cyclical	-1.0%	-1.2%	0.6%	0.0%
Defensive	0.9%	0.6%	1.2%	3.5%
Cyclical xEnergy / Defensive				
Cyclical xEnergy	-1.1%	-2.1%	-2.9%	-4.6%
Momentum				
High Momentum	-0.6%	0.5%	-1.0%	-1.7%
Low Momentum	0.3%	0.4%	1.0%	-5.1%
Size (Small / Large)				
Small Cap	0.0%	-0.9%	-0.8%	-7.6%
Large Cap	0.2%	0.8%	0.8%	7.1%

Source: Clarifi, Morgan Stanley Research

[Exhibit 15](#) shows performance of these pairs in time series graph form.



**Exhibit 15: Cumulative Factor Performance Since 2021**

Source: Clarifi, Morgan Stanley Research

We include an extensive list of factors and their returns in [Exhibit 16](#). We break down the factor spread return by their long and short portfolio and display the top and bottom performing portfolio legs last month in [Exhibit 17](#).



Exhibit 16: Full List of Factor Spread Returns (Long - Short)

Equal Weighted Factor Return (Spread) in Top 1000 as of Mar 31, 2022					
Factor Name	1 Week	1 Month	3 Month	YTD	12 Months
Accruals (Low vs High)	1.2%	3.2%	9.1%	9.0%	16.5%
Composite Accruals (Low vs High)	0.7%	2.9%	7.9%	7.6%	10.7%
Y/Y Change in number of employees (Low vs High)	0.8%	2.6%	13.6%	13.4%	18.0%
Inventory-to-Sales (Low vs High)	1.5%	2.5%	2.8%	2.7%	4.1%
Long-Term Operating Leverage (High vs Low)	0.3%	2.2%	2.9%	2.8%	0.7%
Operating Leverage (High vs Low)	1.0%	1.9%	5.4%	5.1%	10.5%
Value vs Growth	0.6%	1.5%	15.2%	14.8%	18.1%
Incremental Margin (High vs Low)	0.1%	1.4%	3.4%	3.3%	6.6%
Cash-to-Assets (High vs Low)	0.2%	1.4%	-7.1%	-6.6%	-20.4%
Quality vs Junk	0.6%	1.3%	3.5%	3.1%	13.4%
Inventory Turnover (High vs Low)	1.0%	1.2%	5.1%	5.1%	10.4%
Net Cash Variability (Low vs High)	-0.7%	1.1%	3.8%	3.7%	11.6%
Financial Leverage (Low vs High)	-0.4%	1.1%	-1.1%	-1.1%	7.6%
Tangible Book/Price (Cheap vs Expensive)	-1.0%	1.0%	2.0%	2.1%	-3.7%
Price-to-Cash Flow (Cheap vs Expensive)	-0.5%	0.9%	-2.2%	-2.1%	-10.3%
Cash Flow Coverage (High vs Low)	-1.1%	0.8%	0.1%	0.1%	-2.7%
Cash-to-Debt (High vs Low)	-0.2%	0.7%	-6.2%	-5.7%	-17.1%
Operational Efficiency (High vs Low)	0.0%	0.6%	9.4%	9.3%	12.5%
Cash Flow / Debt (High vs Low)	-1.2%	0.6%	0.6%	0.2%	18.0%
9-Month Price Momentum (High vs Low)	-1.3%	0.6%	-3.5%	-4.1%	0.3%
Cash-to-Market Cap (High vs Low)	-1.2%	0.5%	3.9%	4.3%	-4.4%
Earnings Stability (High vs Low)	1.2%	0.5%	2.6%	2.4%	13.5%
Operating Income Variability (Low vs High)	1.4%	0.4%	-4.8%	-4.6%	-5.7%
1-Year EPS Growth (High vs Low)	-0.3%	0.4%	2.5%	2.1%	11.9%
Free Cash Flow-to-Debt (High vs Low)	-0.8%	0.4%	0.5%	0.0%	18.9%
Net Debt-to-Market Cap (Low vs High)	-0.2%	0.4%	-11.9%	-11.6%	-17.5%
Sales Variability (Low vs High)	0.6%	0.4%	6.9%	6.6%	15.4%
Cash Ratio (High vs Low)	0.7%	0.3%	-8.2%	-7.8%	-22.9%
6-Month Price Momentum (High vs Low)	-1.2%	0.3%	-0.6%	-1.1%	4.8%
Reduction in Shares Outstanding (Low vs High)	-0.5%	0.2%	6.7%	6.2%	22.8%
CapEx-to-Depreciation (Low vs High)	0.9%	0.1%	7.8%	7.5%	6.2%
12-Month Price Momentum (High vs Low)	-1.0%	0.1%	-1.5%	-2.1%	3.4%
Composite Quality (High vs Low)	0.6%	0.1%	1.4%	1.1%	12.9%
Operating Margin (High vs Low)	-0.5%	0.1%	2.3%	1.8%	16.5%
Analyst Coverage (High vs Low)	-0.3%	0.1%	1.0%	1.2%	9.0%
Debt-to-EBITDA (Low vs High)	-0.1%	0.1%	-6.6%	-5.9%	-8.8%
Net Cash Ratio (High vs Low)	-0.4%	0.1%	-9.8%	-9.5%	-14.9%
Debt-to-Capital (Low vs High)	-0.3%	0.1%	-5.3%	-5.2%	-10.8%
Enterprise Value-to-Free Cash Flow (Low vs High)	-1.7%	0.1%	12.4%	11.9%	29.0%
1-Month Reversal (Low vs High)	0.9%	0.0%	-7.5%	-7.0%	-7.9%
Free Cash Flow Yield (High vs Low)	-1.4%	0.0%	12.3%	11.8%	27.3%
Sales per Employee (High vs Low)	-1.3%	-0.1%	1.4%	1.5%	5.1%
Y/Y Change in Inventory/Sales (Low vs High)	-0.3%	-0.2%	1.5%	1.5%	3.4%
Debt-to-Assets (Low vs High)	-0.7%	-0.2%	-4.6%	-4.6%	-4.8%
Debt-to-Equity (Low vs High)	-0.5%	-0.2%	-5.0%	-4.9%	-4.6%
Receivables Turnover (High vs Low)	-0.4%	-0.3%	0.8%	0.9%	3.5%
Short-Term Accruals (Low vs High)	-0.1%	-0.3%	1.8%	1.7%	-3.0%
Composite Value (Cheap vs Expensive)	-1.5%	-0.3%	8.7%	8.3%	20.6%
Trailing Dividend Yield (High vs Low)	0.2%	-0.3%	6.7%	6.7%	-2.1%
Forecast long term growth (High vs Low)	-0.6%	-0.3%	-2.1%	-2.1%	-0.1%
Gross Margin (High vs Low)	0.8%	-0.5%	-4.4%	-4.3%	-5.3%
Sales Growth Stability (High vs Low)	1.0%	-0.5%	-1.5%	-1.6%	7.0%
Composite Free Cash Flow (High vs Low)	-1.6%	-0.6%	11.5%	11.0%	27.8%
12m Volatility (Low vs High)	0.5%	-0.6%	3.3%	2.7%	19.9%
3-Month Price Momentum (High vs Low)	-0.8%	-0.6%	-1.5%	-2.0%	1.2%
Price-to-Book (Cheap vs Expensive)	-0.9%	-0.7%	8.8%	8.6%	3.9%
CapEx-to-Assets (Low vs High)	0.1%	-0.7%	0.0%	0.0%	-9.0%
Reinvestment Rate (High vs Low)	0.5%	-0.8%	-1.0%	-1.0%	3.4%
Estimate Dispersion (Low vs High)	0.5%	-0.8%	1.7%	1.3%	16.1%
CapEx-to-Sales (Low vs High)	-0.2%	-0.8%	1.4%	1.3%	-0.1%
Industry Cyclical vs Defensive	-2.1%	-0.8%	-0.5%	-0.9%	2.9%
Total Yield (High vs Low)	-0.8%	-0.9%	3.2%	3.3%	2.1%
ROE (High vs Low)	-0.2%	-0.9%	0.2%	-0.4%	15.3%
Dividend Payout Ratio (High vs Low)	0.8%	-0.9%	-0.4%	-0.3%	1.3%
Price-to-Sales (Cheap vs Expensive)	-1.9%	-1.0%	13.4%	13.0%	24.1%
1-Month Estimate Revisions (%) (High vs Low)	-1.0%	-1.1%	-4.0%	-4.4%	-7.1%
EPS Variability (Low vs High)	0.4%	-1.1%	-2.1%	-2.3%	2.7%
Net Margin (High vs Low)	-0.5%	-1.1%	0.9%	0.3%	17.1%
12m-1m Residual Momentum (High vs Low)	-1.1%	-1.2%	-3.1%	-3.6%	4.5%
Composite Growth (High vs Low)	-0.7%	-1.2%	-0.5%	-0.8%	4.8%
Up-to-Down Revisions (High vs Low)	-1.4%	-1.3%	0.0%	-0.3%	7.1%
Smoothed Estimate Revisions (%) (High vs Low)	-1.2%	-1.4%	-2.6%	-2.8%	4.1%
Sales Estimate Revisions (High vs Low)	-1.0%	-1.5%	-3.5%	-3.8%	0.7%
Return on Invested Capital (High vs Low)	-1.1%	-1.5%	3.0%	2.3%	20.5%
Profitability (High vs Low)	0.1%	-1.6%	-3.7%	-3.7%	5.3%
Composite Sentiment (High vs Low)	-1.0%	-1.6%	-6.2%	-6.3%	-2.3%
5-Year EPS Growth (High vs Low)	-1.3%	-1.7%	-5.6%	-5.7%	-1.6%
Up vs Down Sales Revisions (High vs Low)	-0.9%	-1.7%	-5.1%	-5.3%	-0.2%
Size (Small vs Large)	-0.2%	-1.7%	-1.7%	-1.6%	-14.7%
Enterprise Value-to-EBITDA (Low vs High)	-2.6%	-1.7%	13.7%	13.0%	30.2%
Earnings Estimate Revisions (High vs Low)	-1.8%	-1.8%	-2.3%	-2.7%	4.0%
Earnings Revisions (High vs Low)	-1.9%	-1.8%	-1.3%	-1.6%	6.6%
ROE Variability (Low vs High)	0.1%	-1.8%	-4.6%	-4.8%	0.5%
Sales Revisions (High vs Low)	-1.1%	-1.9%	-3.9%	-4.1%	1.1%
Asset Turnover (High vs Low)	-1.8%	-1.9%	2.1%	1.9%	14.7%
Cyclical vs Defensive	-1.9%	-1.9%	-0.6%	-0.6%	-3.5%
Price-to-Forward Earnings (Cheap vs Expensive)	-1.9%	-1.9%	12.4%	12.0%	30.0%
Price-to-EBITDA (Cheap vs Expensive)	-2.2%	-2.1%	13.4%	12.7%	26.8%
ROA (High vs Low)	-1.5%	-2.3%	0.4%	-0.2%	17.3%
Price-to-Operating Income (Cheap vs Expensive)	-2.3%	-2.3%	11.1%	10.4%	25.5%
1-Year Dividend per share growth (High vs Low)	-1.3%	-2.4%	-3.5%	-3.7%	-1.5%
Enterprise Value-to-Operating Income (Low vs High)	-2.7%	-2.4%	11.6%	10.9%	29.7%
Interest Coverage (High vs Low)	-1.7%	-2.5%	-2.9%	-3.5%	15.8%
Price-to-Earnings (Cheap vs Expensive)	-1.7%	-2.6%	7.6%	7.0%	19.6%
1-Year Sales Growth (High vs Low)	-1.5%	-2.9%	-13.0%	-12.8%	-12.5%
5-Year Dividend per share growth (High vs Low)	-1.6%	-3.1%	-5.4%	-5.6%	-1.7%
5-Year Sales Growth (High vs Low)	-2.0%	-3.2%	-13.2%	-12.8%	-17.2%
Gross Profit / Assets (High vs Low)	-1.2%	-3.6%	-7.9%	-7.7%	-2.5%

Source: Clarifi, Morgan Stanley Research

Exhibit 17: Best and Worst Performing Factor Leg Returns


Best 20 Performing Equal Weighted Group Return in Top 1000 as of Mar 31, 2022					
Group	1 Week	1 Month	3 Month	YTD	12 Months
Top 1000 (Equal Weighted)	0.2%	1.7%	-5.8%	-5.7%	3.7%
Low 5-Year Dividend per share growth	1.3%	3.8%	1.1%	1.2%	13.0%
Low 1-Year Dividend per share growth	1.0%	3.8%	0.9%	0.8%	15.8%
Low 1-Year Sales Growth	1.0%	3.5%	0.0%	0.2%	6.3%
Low Gross Profit / Assets	0.7%	3.5%	-3.7%	-3.5%	0.2%
Low Composite Accruals	0.3%	3.4%	-3.2%	-3.2%	5.0%
High Inventory Turnover	0.7%	3.4%	-0.7%	-0.8%	12.0%
Low Interest Coverage	1.6%	3.3%	-5.6%	-5.1%	-7.3%
Low Inventory-to-Sales	0.7%	3.3%	-4.6%	-4.6%	2.1%
High Price-to-Operating Income	1.3%	3.2%	-11.9%	-11.3%	-15.1%
High ROE Variability	0.5%	3.2%	-2.5%	-2.4%	6.8%
Low ROA	1.2%	3.1%	-8.9%	-8.4%	-9.9%
High Price-to-EBITDA	1.3%	3.1%	-12.8%	-12.2%	-15.3%
Low 5-Year Sales Growth	1.1%	3.1%	-0.8%	-0.8%	6.7%
High Enterprise Value-to-Operating Income	1.5%	3.1%	-12.2%	-11.6%	-16.3%
Low Accruals	0.4%	3.1%	-3.9%	-3.8%	7.1%
Low Net Debt-to-Market Cap	0.3%	3.0%	-12.0%	-11.5%	-9.2%
High Operating Leverage	1.0%	3.0%	-2.6%	-2.6%	6.5%
Low Asset Turnover	1.1%	3.0%	-8.5%	-8.3%	-7.6%
Low Dividend Payout Ratio	0.1%	3.0%	-1.8%	-2.0%	9.0%
High Cash-to-Assets	0.6%	3.0%	-10.5%	-10.1%	-10.0%

Worst 20 Performing Equal Weighted Group Return in Top 1000 as of Mar 31, 2022					
Group	1 Week	1 Month	3 Month	YTD	12 Months
Top 1000 (Equal Weighted)	0.2%	1.7%	-5.8%	-5.7%	3.7%
Low Enterprise Value-to-Operating Income	-1.2%	0.6%	-0.7%	-0.7%	13.4%
High Sales Revisions	-0.4%	0.6%	-8.5%	-8.5%	2.5%
High Smoothed Estimate Revisions (%)	-0.5%	0.6%	-7.7%	-7.7%	-0.9%
High 1-Year Sales Growth	-0.5%	0.6%	-12.9%	-12.6%	-6.2%
Low Y/Y Change in Inventory/Sales	-0.5%	0.6%	-6.3%	-6.3%	4.8%
High Sales Estimate Revisions	-0.7%	0.6%	-7.0%	-7.0%	5.6%
High Earnings Revisions	-1.1%	0.5%	-6.3%	-6.3%	7.5%
Low Price-to-Forward Earnings	-0.8%	0.5%	-0.7%	-0.6%	14.5%
Cyclical	-0.8%	0.5%	-5.1%	-5.1%	3.8%
High Up vs Down Sales Revisions	-0.2%	0.5%	-9.1%	-9.1%	1.5%
High Composite Accruals	-0.4%	0.5%	-11.1%	-10.8%	-5.7%
High Net Cash Variability	0.6%	0.4%	-7.6%	-7.5%	-0.7%
Low Price-to-Earnings	-0.9%	0.3%	-1.9%	-1.9%	10.6%
High Profitability	0.2%	0.3%	-9.2%	-9.0%	3.2%
High Earnings Estimate Revisions	-1.2%	0.2%	-6.6%	-6.6%	5.9%
High Accruals	-0.8%	-0.1%	-13.0%	-12.8%	-9.4%
High Gross Profit / Assets	-0.6%	-0.1%	-11.5%	-11.2%	-2.4%
High 5-Year EPS Growth	-0.7%	-0.2%	-9.1%	-9.1%	3.3%
High 5-Year Sales Growth	-0.9%	-0.2%	-14.0%	-13.6%	-10.5%
High Y/Y Change in number of employees	-0.2%	-0.3%	-13.4%	-13.2%	-8.0%

Source: Clarifi, Morgan Stanley Research

In [Exhibit 18](#), we continue to monitor a number of dispersion metrics on a long-term and short-term basis. For most forms of dispersion, 2021 marked a local peak with these measures falling back towards/below long-term averages. Stock specific risk remains muted as geopolitical uncertainty and macro risk prevail. Return dispersion has risen for most of 2022 but recently saw a tightening in back half of March with the latest market rally.

**Exhibit 18: US Top 500 Dispersion Metrics: Long-term and Short-Term**



Source: Clarifi, Morgan Stanley Research

Lastly, we monitor these dispersion metrics on a percentile basis relative to history ([Exhibit 19](#)). Return dispersion remains historically elevated but has declined in recent weeks. Valuations dispersion per earnings yield and book/price differs widely by industry group with elevated readings in consumer sectors (Food & Staples Retailing and Consumer Durables). Lastly, S&P 500 earnings estimate dispersion is historically high across most industries with Utilities and Telecom Services as the outliers at near all-time dispersion lows.

**Exhibit 19:** Historical Dispersion Metrics by Industry Group

	Percentile Since 2000			
	Return Dispersion	Earning Yield Dispersion	Book/Price Dispersion	Earnings Estimate Dispersion
<b>S&amp;P 500</b>	65%	50%	31%	85%
Energy	19%	9%	25%	62%
Materials	10%	72%	16%	64%
Capital Goods	66%	81%	54%	77%
Commercial & Professional Services	19%	66%	92%	78%
Transportation	67%	48%	8%	69%
Automobiles & Components	26%	83%	77%	68%
Consumer Durables & Apparel	58%	86%	95%	85%
Consumer Services	84%	77%	32%	93%
Retailing	83%	66%	13%	65%
Food & Staples Retailing	97%	91%	97%	91%
Food, Beverage & Tobacco	33%	56%	49%	82%
Household & Personal Products	81%	43%	0%	86%
Health Care Equipment & Services	64%	40%	38%	70%
Pharma, Biotech & Life Sciences	46%	85%	87%	89%
Banks	56%	74%	46%	80%
Diversified Financials	72%	87%	50%	84%
Insurance	40%	53%	62%	90%
Software & Services	71%	30%	46%	77%
Technology Hardware & Equipment	80%	68%	66%	20%
Semiconductors & Semi Equipment	83%	45%	49%	31%
Telecommunication Services	34%	40%	40%	0%
Media & Entertainment	47%	47%	50%	89%
Utilities	19%	26%	53%	6%
Real Estate	75%	54%	32%	73%

Source: Clarifi, Morgan Stanley Research

# Fresh Money Buy List


**Exhibit 20: Fresh Money Buy List - Stats & Performance**

Company Name	Ticker	MS Rating	Sector	Market Cap (\$Bn)	Price	MS PT	% to MS PT	MS Analyst	Date Added	Total Return Since Inclusion	
										Absolute	Rel. to S&P
AT&T, Inc.	T	Overweight	Communication Services	\$171.1	\$23.96	28.00	16.9%	Flannery, Simon	12/20/2021	2.7%	4.1%
CenterPoint Energy Inc	CNP	Overweight	Utilities	\$19.6	\$31.22	31.00	(0.7%)	Byrd, Stephen	3/21/2022	7.5%	5.7%
Coca-Cola Co.	KO	Overweight	Consumer Staples	\$272.4	\$62.83	76.00	21.0%	Mohsenian, Dara	3/28/2022	2.1%	2.2%
Exxon Mobil Corporation	XOM	Overweight	Energy	\$351.7	\$83.06	95.00	14.4%	McDermott, Devin	2/22/2021	67.4%	49.4%
Humana Inc	HUM	Equal-Weight	Health Care	\$56.0	\$441.85	436.00	(1.3%)	Goldwasser, Ricky	7/19/2018	43.1%	(28.9%)
McDonald's Corporation	MCD	Overweight	Consumer Discretionary	\$185.1	\$248.90	287.00	15.3%	Glass, John	10/18/2021	3.9%	1.8%
Mondelez International Inc	MDLZ	Overweight	Consumer Staples	\$88.2	\$63.53	73.00	14.9%	Kaufman, Pamela	7/19/2021	0.5%	(5.4%)
SBA Communications	SBAC	Overweight	Real Estate	\$37.9	\$350.61	384.00	9.5%	Flannery, Simon	6/7/2021	12.7%	4.2%
Simon Property Group Inc	SPG	Overweight	Real Estate	\$43.7	\$132.96	160.00	20.3%	Hill, Richard	2/16/2021	28.7%	11.5%
Welltower Inc.	WELL	Overweight	Real Estate	\$43.7	\$97.64	100.00	2.4%	Hill, Richard	2/22/2021	47.1%	29.1%
<b>Current List Performance</b>											
Average (Eq. Weight)				\$126.9			11.3%			21.6%	7.4%
Median				\$72.1			14.6%			10.1%	4.2%
% Positive Returns (Abs. / Rel.)										100%	80%
% Negative Returns (Abs. / Rel.)										0%	20%
Avg. Hold Period (Months)											11.3
<b>All Time List Performance</b>											
Average (Eq. Weight)										31.3%	12.6%
Median										19.2%	4.2%
% Positive Returns (Abs. / Rel.)										81%	59%
% Negative Returns (Abs. / Rel.)										21%	41%
Avg. Hold Period (Months)											13.1


Performance returns shown above and below represent local currency total returns, including dividends and excluding brokerage commission. Returns are calculated using the closing price on the last trading day before the date shown in the "Date Added" column through close on the last trading day prior to publication of this report for stocks currently on the list and through close on the day of removal for stocks formerly on the list. These figures are not audited. Past performance is no guarantee of future results.

++ Rating and other information has been removed from consideration in this report because, under applicable law and/or Morgan Stanley policy, Morgan Stanley may be precluded from issuing such information with respect to this company at this time.

Source: Bloomberg, Morgan Stanley Research estimates.

**Exhibit 21: Fresh Money Buy List & S&P 500 Cumulative Total Return**


Source: Bloomberg, Morgan Stanley Research.

**Exhibit 22: Fresh Money Buy List / S&P 500 Cumulative Relative Return**


Source: Bloomberg, Morgan Stanley Research.

**McDonald's (MCD), John Glass**

- **1Q22 Commodities Update: Food Costs Taking Another Bite:** Our index increased 28% y/y in 1Q, with chicken breast and corn the biggest drivers. With geopolitical developments added, crops and produce drove our index up in March 8% m/m to a new high. This price spike could pose a risk to 2H margin forecasts which contemplate some alleviation in inflation.
- Our commodity index increased 28% y/y in 1Q22 and rose 3% above 4Q21 levels to a new high again. Some poultry items and corn were most inflationary similar to prior months. The Morgan Stanley Commodity Index averaged 251 in 1Q vs 243 in 4Q21 and 196 in 1Q21. On a y/y basis, chicken breast (+7 pts), corn (+4 pts), coffee (+3 pts), and ground beef (+3 pts) led the increase, while tomatoes (-1 pt) declined the most. Nearly all other components in our index climbed higher y/y. Price inflation in the same items drove y/y growth in the month of March. Crops and produce underpinned an 8% m/m gain in our index, the widest sequential increase since May 2021, in contrast with key proteins as the driver in prior months. Geopolitical developments and production constraints lifted prices of corn (3 pts), lettuce (3 pts), and wheat (2 pts). This more than offset a pullback in chicken wings (-1 pt) and tomatoes (-1 pt). Although driven by seemingly temporary factors that could evolve rapidly, if commodity prices were to hold at current levels, we'd anticipate some downside risk to our current margin expectations for 2H22, which contemplate some reduction in commodity cost inflation as companies lap last year's 2H21 inflation levels. Stocks in our coverage reflect this to some degree and contracting partly protects restaurants from this material spot price inflation, though the risk could drag into 2023 if new contracts are struck at higher prices following recent developments.


## What's Retail Doing?

*Our Quantitative Equity Strategy team recently introduced a novel way to track the activity of retail traders using publicly available data. We provide a few updates and key observations on the retail trader using this approach.*

A few key observations:


- Retail participation is currently at 9.1% of the total market volume, and at 70th %-ile relative to the last 5 years.
- Order imbalance remains positive last week. It currently sits at 0.8% or 76th percentile relative to the last 5 years.
- Imbalance is positive on market level and in most sectors, except in Utilities and Health Care. It is most positive relative to sector history in Staples (95th %-ile), and Financials (92nd %-ile). Staples is most positive in buy/sell imbalance.

**Exhibit 23:** Retail orders as a % of notional traded now above median



Source: Morgan Stanley Research, Morgan Stanley Quantitative and Derivative Strategies, Compustat

**Exhibit 24:** ... and positive in order imbalance



Source: Morgan Stanley Research, Morgan Stanley Quantitative and Derivative Strategies, Compustat

**Exhibit 25:** Retail's buy/sell imbalance is most positive in Staples

Sector	Retail Participation			Buy/Sell Imbalance		
	2016-21 Median	Current	p-tile	2016-21 Median	Current	p-tile
Energy	6.7%	8.6%	0.89	-0.34%	0.4%	0.67
Materials	5.7%	7.3%	0.90	0.5%	0.9%	0.61
Industrials	6.7%	5.8%	0.18	0.0%	1.0%	0.84
Consumer Discretionary	11.3%	11.1%	0.46	0.7%	0.2%	0.24
Consumer Staples	6.1%	5.1%	0.15	-0.5%	2.1%	0.95
Health Care	6.0%	4.1%	0.02	-0.3%	-0.3%	0.54
Financials	5.6%	5.9%	0.64	0.0%	1.9%	0.92
Information Technology	10.8%	12.1%	0.83	0.5%	0.8%	0.65
Communication Services	8.7%	10.1%	0.60	0.3%	1.7%	0.88
Utilities	3.9%	3.4%	0.19	-1.2%	-1.3%	0.48
Real Estate	3.5%	2.8%	0.05	0.6%	1.9%	0.76
<b>Model Universe (Top 1500)</b>	<b>8.5%</b>	<b>9.1%</b>	<b>0.70</b>	<b>0.3%</b>	<b>0.8%</b>	<b>0.76</b>

Source: Morgan Stanley Research, Morgan Stanley Quantitative and Derivative Strategies, Compustat


For more on the methodology, please see [Quantitative Equity Research: The Rise of the Retail Trader \(30 Jun 2021\)](#).




## Weekly Charts to Watch

### Exhibit 26: US Earnings Snapshot


#### S&P 500 Y/Y EPS Growth




#### S&P 500 NTM EPS vs. Total Return Level



#### S&P 500 Earnings Revisions Breadth



#### US Leading Earnings Indicator



Source: Refinitiv, FactSet, Morgan Stanley Research. Top and bottom left: As of Apr 1, 2022 Bottom right As of Feb 28, 2021. MS Leading Earnings Indicator is a macro factor based earnings model that leads actual earnings growth by one year with a 0.7 12-month leading correlation. Note: S&P 500 fundamental data used post March 1993; Top 500 by market cap data used before 1993. LTM equity risk premium average is since 1920. ERP based on forward earnings yield and 10-year Treasury Yield.

### Exhibit 27: S&P 500 Price Target

#### Morgan Stanley S&P 500 Year-End 2022 Price Target

Landscape	Earnings	Multiple	Price Target	Upside / Downside
Bull Case	\$265	18.8x	5,000	10.0%
Base Case	\$245	18.0x	4,400	-3.2%
Bear Case	\$225	17.2x	3,900	-14.2%

Current S&P 500 Price as of: 4/1/2022 4,546


Note: We use 2022YE forward earnings to project our price target which takes into account our 2023YE earnings forecast (currently \$245 base case).  
Source: Bloomberg, Morgan Stanley Research

Exhibit 28: Sector Ratings

Morgan Stanley Sector Recommendations			
Overweight	Utilities	Health Care	Real Estate
	Comm. Services	Energy	Industrials
Neutral	Materials	Staples	Tech ex Hardware
	Financials		
Underweight	Discretionary	Tech Hardware	

Source: Morgan Stanley Research


Exhibit 29: S&P 500 Equity Risk Premium using Nominal Rates and Breakevens




Source: Bloomberg, Morgan Stanley Research. As of Mar 31, 2022

### Exhibit 30: US Equity Market Technicals and Financial Conditions


S&P 500 Cumulative Advance-Decline




S&P 500 Percent Members Above 200-Day Moving Average



S&P 500 with Moving Averages




Morgan Stanley Financial Conditions Index




Source: Bloomberg, Morgan Stanley Research. All: As of Apr 1, 2022

### Exhibit 31: US Small Cap Equities


Russell 2000 NTM EPS vs. Total Return Level




Russell 2000 NTM P/B and Relative NTM P/B vs. S&P 500



Russell 2000 Relative Performance vs. S&P 500




NTM EPS by Cap Size



Source: FactSet, Morgan Stanley Research. As of Apr 1, 2022

Exhibit 32: Earnings Revisions Breadth vs YoY Performance



Source: FactSet, Morgan Stanley Research. As of Mar 25, 2022

*For valuation methodology and risks associated with any price targets referenced in this research report, please contact the Client Support Team as follows: US/Canada +1 800 303-2495; Hong Kong +852 2848-5999; Latin America +1 718 754-5444 (U.S.); London +44 (0)20-7425-8169; Singapore +65 6834-6860; Sydney +61 (0)2-9770-1505; Tokyo +81 (0)3-6836-9000. Alternatively you may contact your investment representative or Morgan Stanley Research at 1585 Broadway (Attention: Research Management), New York, NY 10036 USA.*

## Disclosure Section

The information and opinions in Morgan Stanley Research were prepared by Morgan Stanley & Co. LLC, and/or Morgan Stanley C.T.V.M. S.A., and/or Morgan Stanley Mexico, Casa de Bolsa, S.A. de C.V., and/or Morgan Stanley Canada Limited. As used in this disclosure section, "Morgan Stanley" includes Morgan Stanley & Co. LLC, Morgan Stanley C.T.V.M. S.A., Morgan Stanley Mexico, Casa de Bolsa, S.A. de C.V., Morgan Stanley Canada Limited and their affiliates as necessary.

For important disclosures, stock price charts and equity rating histories regarding companies that are the subject of this report, please see the Morgan Stanley Research Disclosure Website at [www.morganstanley.com/researchdisclosures](http://www.morganstanley.com/researchdisclosures), or contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY, 10036 USA.

For valuation methodology and risks associated with any recommendation, rating or price target referenced in this research report, please contact the Client Support Team as follows: US/Canada +1 800 303-2495; Hong Kong +852 2848-5999; Latin America +1 718 754-5444 (U.S.); London +44 (0)20-7425-8169; Singapore +65 6834-6860; Sydney +61 (0)2-9770-1505; Tokyo +81 (0)3-6836-9000. Alternatively you may contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY 10036 USA.

### Analyst Certification

The following analysts hereby certify that their views about the companies and their securities discussed in this report are accurately expressed and that they have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report: Diane Ding, Ph.D.; Nicholas Lentini, CFA; Andrew B Pauker; Michelle M. Weaver, CFA; Michael J Wilson.

### Global Research Conflict Management Policy

Morgan Stanley Research has been published in accordance with our conflict management policy, which is available at [www.morganstanley.com/institutional/research/conflictpolicies](http://www.morganstanley.com/institutional/research/conflictpolicies). A Portuguese version of the policy can be found at [www.morganstanley.com.br](http://www.morganstanley.com.br)

### Important Regulatory Disclosures on Subject Companies

The analyst or strategist (or a household member) identified below owns the following securities (or related derivatives): Diane Ding, Ph.D. - Simon Property Group Inc (common or preferred stock).

As of February 28, 2022, Morgan Stanley beneficially owned 1% or more of a class of common equity securities of the following companies covered in Morgan Stanley Research: AT&T, Inc., CenterPoint Energy Inc, Coca-Cola Co., Exxon Mobil Corporation, Humana Inc, MasterCard Inc, McDonald's Corporation, Mondelez International Inc, SBA Communications, Simon Property Group Inc, Synchrony Financial, Welltower Inc..

Within the last 12 months, Morgan Stanley managed or co-managed a public offering (or 144A offering) of securities of CenterPoint Energy Inc, Coca-Cola Co., Humana Inc, MasterCard Inc, Mondelez International Inc, Welltower Inc..

Within the last 12 months, Morgan Stanley has received compensation for investment banking services from CenterPoint Energy Inc, Coca-Cola Co., Exxon Mobil Corporation, Humana Inc, MasterCard Inc, McDonald's Corporation, Mondelez International Inc, Simon Property Group Inc, Welltower Inc..

In the next 3 months, Morgan Stanley expects to receive or intends to seek compensation for investment banking services from AT&T, Inc., CenterPoint Energy Inc, Coca-Cola Co., Exxon Mobil Corporation, Humana Inc, MasterCard Inc, McDonald's Corporation, Mondelez International Inc, SBA Communications, Simon Property Group Inc, Synchrony Financial, Welltower Inc..

Within the last 12 months, Morgan Stanley has received compensation for products and services other than investment banking services from AT&T, Inc., CenterPoint Energy Inc, Coca-Cola Co., Exxon Mobil Corporation, Humana Inc, MasterCard Inc, McDonald's Corporation, Mondelez International Inc, Simon Property Group Inc, Welltower Inc..

Within the last 12 months, Morgan Stanley has provided or is providing investment banking services to, or has an investment banking client relationship with, the following company: AT&T, Inc., CenterPoint Energy Inc, Coca-Cola Co., Exxon Mobil Corporation, Humana Inc, MasterCard Inc, McDonald's Corporation, Mondelez International Inc, SBA Communications, Simon Property Group Inc, Synchrony Financial, Welltower Inc..

Within the last 12 months, Morgan Stanley has either provided or is providing non-investment banking, securities-related services to and/or in the past has entered into an agreement to provide services or has a client relationship with the following company: AT&T, Inc., CenterPoint Energy Inc, Coca-Cola Co., Exxon Mobil Corporation, Humana Inc, MasterCard Inc, McDonald's Corporation, Mondelez International Inc, Simon Property Group Inc, Synchrony Financial, Welltower Inc..

An employee, director or consultant of Morgan Stanley is a director of AT&T, Inc.. This person is not a research analyst or a member of a research analyst's household.

Morgan Stanley & Co. LLC makes a market in the securities of AT&T, Inc., CenterPoint Energy Inc, Coca-Cola Co., Exxon Mobil Corporation, MasterCard Inc, McDonald's Corporation, Mondelez International Inc, SBA Communications, Simon Property Group Inc, Synchrony Financial, Welltower Inc..

The equity research analysts or strategists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors, firm revenues and overall investment banking revenues. Equity Research analysts' or strategists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.

Morgan Stanley and its affiliates do business that relates to companies/instruments covered in Morgan Stanley Research, including market making, providing liquidity, fund management, commercial banking, extension of credit, investment services and investment banking. Morgan Stanley sells to and buys from customers the securities/instruments of companies covered in Morgan Stanley Research on a principal basis. Morgan Stanley may have a position in the debt of the Company or instruments discussed in this report. Morgan Stanley trades or may trade as principal in the debt securities (or in related derivatives) that are the subject of the debt research report.

Certain disclosures listed above are also for compliance with applicable regulations in non-US jurisdictions.

### STOCK RATINGS

Morgan Stanley uses a relative rating system using terms such as Overweight, Equal-weight, Not-Rated or Underweight (see definitions below). Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold and sell. Investors should carefully read the definitions of all ratings used in Morgan Stanley Research. In addition, since Morgan Stanley Research contains more complete information concerning the analyst's views, investors should carefully read Morgan Stanley Research, in its entirety, and not infer the contents from the rating alone. In any case, ratings (or research) should not be used or relied upon as investment advice. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations.

### Global Stock Ratings Distribution

(as of March 31, 2022)

The Stock Ratings described below apply to Morgan Stanley's Fundamental Equity Research and do not apply to Debt Research produced by the Firm. For disclosure purposes only (in accordance with FINRA requirements), we include the category headings of Buy, Hold, and Sell alongside our ratings of Overweight, Equal-weight, Not-Rated and Underweight. Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold, and sell but represent recommended relative weightings (see definitions below).

To satisfy regulatory requirements, we correspond Overweight, our most positive stock rating, with a buy recommendation; we correspond Equal-weight and Not-Rated to hold and Underweight to sell recommendations, respectively.

STOCK RATING CATEGORY	COVERAGE UNIVERSE		INVESTMENT BANKING CLIENTS (IBC)			OTHER MATERIAL INVESTMENT SERVICES CLIENTS (MISC)	
	COUNT	% OF TOTAL	COUNT	% OF TOTAL IBC	% OF RATING CATEGORY	COUNT	% OF TOTAL OTHER MSC
Overweight/Buy	1438	41%	366	45%	25%	630	41%
Equal-weight/Hold	1539	44%	365	45%	24%	712	46%
Not-Rated/Hold	0	0%	0	0%	0%	0	0%
Underweight/Sell	552	16%	87	11%	16%	207	13%
<b>TOTAL</b>	<b>3,529</b>		<b>818</b>			<b>1549</b>	

Data include common stock and ADRs currently assigned ratings. Investment Banking Clients are companies from whom Morgan Stanley received investment banking compensation in the last 12 months. Due to rounding off of decimals, the percentages provided in the "% of total" column may not add up to exactly 100 percent.

### Analyst Stock Ratings

Overweight (O). The stock's total return is expected to exceed the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Equal-weight (E). The stock's total return is expected to be in line with the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Not-Rated (NR). Currently the analyst does not have adequate conviction about the stock's total return relative to the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Underweight (U). The stock's total return is expected to be below the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.

Unless otherwise specified, the time frame for price targets included in Morgan Stanley Research is 12 to 18 months.

### Analyst Industry Views

Attractive (A): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be attractive vs. the relevant broad market benchmark, as indicated below.

In-Line (I): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be in line with the relevant broad market benchmark, as indicated below.

Cautious (C): The analyst views the performance of his or her industry coverage universe over the next 12-18 months with caution vs. the relevant broad market benchmark, as indicated below.

Benchmarks for each region are as follows: North America - S&P 500; Latin America - relevant MSCI country index or MSCI Latin America Index; Europe - MSCI Europe; Japan - TOPIX; Asia - relevant MSCI country index or MSCI sub-regional index or MSCI AC Asia Pacific ex Japan Index.

### Important Disclosures for Morgan Stanley Smith Barney LLC & E\*TRADE Securities LLC Customers

Important disclosures regarding the relationship between the companies that are the subject of Morgan Stanley Research and Morgan Stanley Smith Barney LLC or Morgan Stanley or any of their affiliates, are available on the Morgan Stanley Wealth Management disclosure website at

[www.morganstanley.com/online/researchdisclosures](http://www.morganstanley.com/online/researchdisclosures). For Morgan Stanley specific disclosures, you may refer to

[www.morganstanley.com/researchdisclosures](http://www.morganstanley.com/researchdisclosures).

Each Morgan Stanley research report is reviewed and approved on behalf of Morgan Stanley Smith Barney LLC and E\*TRADE Securities LLC. This review and approval is conducted by the same person who reviews the research report on behalf of Morgan Stanley. This could create a conflict of interest.

### Other Important Disclosures

Morgan Stanley & Co. International PLC and its affiliates have a significant financial interest in the debt securities of AT&T, Inc., CenterPoint Energy Inc, Coca-Cola Co., Exxon Mobil Corporation, Humana Inc, MasterCard Inc, McDonald's Corporation, Mondelez International Inc, Synchrony Financial, Welltower Inc..

Morgan Stanley Research policy is to update research reports as and when the Research Analyst and Research Management deem appropriate, based on developments with the issuer, the sector, or the market that may have a material impact on the research views or opinions stated therein. In addition, certain Research publications are intended to be updated on a regular periodic basis (weekly/monthly/quarterly/annual) and will ordinarily be updated with that frequency, unless the Research Analyst and Research Management determine that a different publication schedule is appropriate based on current conditions.

Morgan Stanley is not acting as a municipal advisor and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of Section 975 of the Dodd-Frank Wall Street Reform and Consumer Protection Act.

Morgan Stanley produces an equity research product called a "Tactical Idea." Views contained in a "Tactical Idea" on a particular stock may be contrary to the recommendations or views expressed in research on the same stock. This may be the result of differing time horizons, methodologies, market events, or other factors. For all research available on a particular stock, please contact your sales representative or go to Matrix at <http://www.morganstanley.com/matrix>.

Morgan Stanley Research is provided to our clients through our proprietary research portal on Matrix and also distributed electronically by Morgan Stanley to clients. Certain, but not all, Morgan Stanley Research products are also made available to clients through third-party vendors or redistributed to clients through alternate electronic means as a convenience. For access to all available Morgan Stanley Research, please contact your sales representative or go to Matrix at <http://www.morganstanley.com/matrix>.

Any access and/or use of Morgan Stanley Research is subject to Morgan Stanley's Terms of Use (<http://www.morganstanley.com/terms.html>). By accessing and/or using Morgan Stanley Research, you are indicating that you have read and agree to be bound by our Terms of Use

(<http://www.morganstanley.com/terms.html>). In addition you consent to Morgan Stanley processing your personal data and using cookies in accordance with our Privacy Policy and our Global Cookies Policy ([http://www.morganstanley.com/privacy\\_pledge.html](http://www.morganstanley.com/privacy_pledge.html)), including for the purposes of setting your preferences and to collect readership data so that we can deliver better and more personalized service and products to you. To find out more information about how Morgan Stanley processes personal data, how we use cookies and how to reject cookies see our Privacy Policy and our Global Cookies Policy



([http://www.morganstanley.com/privacy\\_pledge.html](http://www.morganstanley.com/privacy_pledge.html)).

If you do not agree to our Terms of Use and/or if you do not wish to provide your consent to Morgan Stanley processing your personal data or using cookies please do not access our research.

Morgan Stanley Research does not provide individually tailored investment advice. Morgan Stanley Research has been prepared without regard to the circumstances and objectives of those who receive it. Morgan Stanley recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. The appropriateness of an investment or strategy will depend on an investor's circumstances and objectives. The securities, instruments, or strategies discussed in Morgan Stanley Research may not be suitable for all investors, and certain investors may not be eligible to purchase or participate in some or all of them. Morgan Stanley Research is not an offer to buy or sell or the solicitation of an offer to buy or sell any security/instrument or to participate in any particular trading strategy. The value of and income from your investments may vary because of changes in interest rates, foreign exchange rates, default rates, prepayment rates, securities/instruments prices, market indexes, operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in securities/instruments transactions. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. If provided, and unless otherwise stated, the closing price on the cover page is that of the primary exchange for the subject company's securities/instruments.

The fixed income research analysts, strategists or economists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality, accuracy and value of research, firm profitability or revenues (which include fixed income trading and capital markets profitability or revenues), client feedback and competitive factors. Fixed Income Research analysts', strategists' or economists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.

The "Important Regulatory Disclosures on Subject Companies" section in Morgan Stanley Research lists all companies mentioned where Morgan Stanley owns 1% or more of a class of common equity securities of the companies. For all other companies mentioned in Morgan Stanley Research, Morgan Stanley may have an investment of less than 1% in securities/instruments or derivatives of securities/instruments of companies and may trade them in ways different from those discussed in Morgan Stanley Research. Employees of Morgan Stanley not involved in the preparation of Morgan Stanley Research may have investments in securities/instruments or derivatives of securities/instruments of companies mentioned and may trade them in ways different from those discussed in Morgan Stanley Research. Derivatives may be issued by Morgan Stanley or associated persons.

With the exception of information regarding Morgan Stanley, Morgan Stanley Research is based on public information. Morgan Stanley makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete. We have no obligation to tell you when opinions or information in Morgan Stanley Research change apart from when we intend to discontinue equity research coverage of a subject company. Facts and views presented in Morgan Stanley Research have not been reviewed by, and may not reflect information known to, professionals in other Morgan Stanley business areas, including investment banking personnel.

Morgan Stanley Research personnel may participate in company events such as site visits and are generally prohibited from accepting payment by the company of associated expenses unless pre-approved by authorized members of Research management.

Morgan Stanley may make investment decisions that are inconsistent with the recommendations or views in this report.

To our readers based in Taiwan or trading in Taiwan securities/instruments: Information on securities/instruments that trade in Taiwan is distributed by Morgan Stanley Taiwan Limited ("MSTL"). Such information is for your reference only. The reader should independently evaluate the investment risks and is solely responsible for their investment decisions. Morgan Stanley Research may not be distributed to the public media or quoted or used by the public media without the express written consent of Morgan Stanley. Any non-customer reader within the scope of Article 7-1 of the Taiwan Stock Exchange Recommendation Regulations accessing and/or receiving Morgan Stanley Research is not permitted to provide Morgan Stanley Research to any third party (including but not limited to related parties, affiliated companies and any other third parties) or engage in any activities regarding Morgan Stanley Research which may create or give the appearance of creating a conflict of interest. Information on securities/instruments that do not trade in Taiwan is for informational purposes only and is not to be construed as a recommendation or a solicitation to trade in such securities/instruments. MSTL may not execute transactions for clients in these securities/instruments.

Morgan Stanley is not incorporated under PRC law and the research in relation to this report is conducted outside the PRC. Morgan Stanley Research does not constitute an offer to sell or the solicitation of an offer to buy any securities in the PRC. PRC investors shall have the relevant qualifications to invest in such securities and shall be responsible for obtaining all relevant approvals, licenses, verifications and/or registrations from the relevant governmental authorities themselves. Neither this report nor any part of it is intended as, or shall constitute, provision of any consultancy or advisory service of securities investment as defined under PRC law. Such information is provided for your reference only.

Morgan Stanley Research is disseminated in Brazil by Morgan Stanley C.T.V.M. S.A. located at Av. Brigadeiro Faria Lima, 3600, 6th floor, São Paulo - SP, Brazil; and is regulated by the Comissão de Valores Mobiliários; in Mexico by Morgan Stanley México, Casa de Bolsa, S.A. de C.V. which is regulated by Comisión Nacional Bancaria y de Valores. Paseo de los Tamarindos 90, Torre 1, Col. Bosques de las Lomas Floor 29, 05120 Mexico City; in Japan by Morgan Stanley MUFG Securities Co., Ltd. and, for Commodities related research reports only, Morgan Stanley Capital Group Japan Co., Ltd; in Hong Kong by Morgan Stanley Asia Limited (which accepts responsibility for its contents) and by Morgan Stanley Asia International Limited, Hong Kong Branch; in Singapore by Morgan Stanley Asia (Singapore) Pte. (Registration number 199206298Z) and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H), regulated by the Monetary Authority of Singapore (which accepts legal responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research) and by Morgan Stanley Asia International Limited, Singapore Branch (Registration number T11FC0207F); in Australia to "wholesale clients" within the meaning of the Australian Corporations Act by Morgan Stanley Australia Limited A.B.N. 67 003 734 576, holder of Australian financial services license No. 233742, which accepts responsibility for its contents; in Australia to "wholesale clients" and "retail clients" within the meaning of the Australian Corporations Act by Morgan Stanley Wealth Management Australia Pty Ltd (A.B.N. 19 009 145 555, holder of Australian financial services license No. 240813, which accepts responsibility for its contents; in Korea by Morgan Stanley & Co International plc, Seoul Branch; in India by Morgan Stanley India Company Private Limited; in Canada by Morgan Stanley Canada Limited, which has approved of and takes responsibility for its contents in Canada; in Germany and the European Economic Area where required by Morgan Stanley Europe S.E., authorised and regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin) under the reference number 149169; in the US by Morgan Stanley & Co. LLC, which accepts responsibility for its contents. Morgan Stanley & Co. International plc, authorized by the Prudential Regulatory Authority and regulated by the Financial Conduct Authority and the Prudential Regulatory Authority, disseminates in the UK research that it has prepared, and approves solely for the purposes of section 21 of the Financial Services and Markets Act 2000, research which has been prepared by any of its affiliates. RMB Morgan Stanley Proprietary Limited is a member of the JSE Limited and A2X (Pty) Ltd. RMB Morgan Stanley Proprietary Limited is a joint venture owned equally by Morgan Stanley International Holdings Inc. and RMB Investment Advisory (Proprietary) Limited, which is wholly owned by FirstRand Limited. The information in Morgan Stanley Research is being disseminated by Morgan Stanley Saudi Arabia, regulated by the Capital Market Authority in the Kingdom of Saudi Arabia, and is directed at Sophisticated investors only.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (DIFC Branch), regulated by the Dubai Financial Services Authority (the DFSA), and is directed at Professional Clients only, as defined by the DFSA. The financial products or financial services to which this research relates will only be made available to a customer who we are satisfied meets the regulatory criteria to be a Professional Client.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (QFC Branch), regulated by the Qatar Financial Centre Regulatory Authority (the QFCRA), and is directed at business customers and market counterparties only and is not intended for Retail Customers as defined by the QFCRA.

As required by the Capital Markets Board of Turkey, investment information, comments and recommendations stated here, are not within the scope of investment advisory activity. Investment advisory service is provided exclusively to persons based on their risk and income preferences by the authorized firms. Comments and recommendations stated here are general in nature. These opinions may not fit to your financial status, risk and return preferences. For this reason, to make an investment decision by relying solely to this information stated here may not bring about outcomes that fit your expectations.

The following companies do business in countries which are generally subject to comprehensive sanctions programs administered or enforced by the U.S. Department of the Treasury's Office of Foreign Assets Control ("OFAC") and by other countries and multi-national bodies: MasterCard Inc.

The trademarks and service marks contained in Morgan Stanley Research are the property of their respective owners. Third-party data providers make no warranties or representations relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages relating to such data. The Global Industry Classification Standard (GICS) was developed by and is the exclusive property of MSCI and S&P.

Morgan Stanley Research, or any portion thereof may not be reprinted, sold or redistributed without the written consent of Morgan Stanley.

Indicators and trackers referenced in Morgan Stanley Research may not be used as, or treated as, a benchmark under Regulation EU 2016/1011, or any other similar framework.

The issuers and/or fixed income products recommended or discussed in certain fixed income research reports may not be continuously followed. Accordingly, investors should regard those fixed income research reports as providing stand-alone analysis and should not expect continuing analysis or additional reports relating to such issuers and/or individual fixed income products.

Morgan Stanley may hold, from time to time, material financial and commercial interests regarding the company subject to the Research report.

© 2022 Morgan Stanley